Kengo Takeuchi

Citée par

	Toutes	Depuis 2020
Citations	24403	8804
indice h	75	47
indice i10	219	151

1900

950

475

1425

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202573 91 89 103 140 249 342 622 959 1298 1454 1609 1732 1688 1641 1537 1569 1645 1891 1741 1646 1656 218

Accès public

Tout afficher

11 articles

2 articles

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Yuki TogashiPathology Project for Molecular Targets, The Cancer Institute, JFCRAdresse e-mail validée de jfcr.or.jp
Ryohei KatayamaJapanese Foundation for Cancer ResearchAdresse e-mail validée de jfcr.or.jp
Seishi OgawaAdresse e-mail validée de umin.ac.jp
Akito DobashiThe Cancer Institute, Japanese Foundation for Cancer ResearchAdresse e-mail validée de umin.ac.jp
Noriko MotoiNational Cancer Center HospitalAdresse e-mail validée de umin.ac.jp
Tadashi YoshinoProfessor of Medicine, Okayama universityAdresse e-mail validée de md.okayama-u.ac.jp
luc fribouletGustave Roussy Université Paris SaclayAdresse e-mail validée de gustaveroussy.fr
Tetsuya MitsudomiKindai UniversityAdresse e-mail validée de med.kindai.ac.jp
Keitaro MatsuoDivision of Cancer Epidemiology and Prevention, Aichi Cancer Center Research InstituteAdresse e-mail validée de aichi-cc.jp
Yuichi ShiraishiNational Cancer CenterAdresse e-mail validée de ncc.go.jp
eiji shinozakiAdresse e-mail validée de jfcr.or.jp
Seiichi MoriGenome Center, Japanese Foundation for Cancer ResearchAdresse e-mail validée de jfcr.or.jp
Hiroto NarimatsuDepartment of Public Health, Yamagata university graduate school of medicineAdresse e-mail validée de umin.org
Miyoshi HiroakiDepartment of Pathology, Kurume University, School of MedicineAdresse e-mail validée de med.kurume-u.ac.jp
Y. YATABEAdresse e-mail validée de ncc.go.jp
Koichiro YujiProject Associate Professor, the Institute of Medical Science, the University of TokyoAdresse e-mail validée de umin.ac.jp
Hironori HagaKyoto UniversityAdresse e-mail validée de kuhp.kyoto-u.ac.jp
HIROSHI IWATABrigham and Women's HospitalAdresse e-mail validée de partners.org
藤井聡, Satoshi Fujii京都大学, Kyoto University, Goteborg UniversityAdresse e-mail validée de trans.kuciv.kyoto-u.ac.jp
Yoichi ImaiThe Institute of Medical Science, The University of TokyoAdresse e-mail validée de umin.ac.jp

Suivre

Kengo Takeuchi

Cancer Institute, Japanese Foundation for Cancer Research

Adresse e-mail validée de umin.net - Page d'accueil

pathology surgical pathology molecular pathology hematopathology lymphoma


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
RET, ROS1 and ALK fusions in lung cancer K Takeuchi, M Soda, Y Togashi, R Suzuki, S Sakata, S Hatano, R Asaka, ... Nature Medicine 18 (3), 378-381, 2012	1634	2012
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors YL Choi, M Soda, Y Yamashita, T Ueno, J Takashima, T Nakajima, ... New England Journal of Medicine 363 (18), 1734-1739, 2010	1479	2010
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer K Takeuchi, YL Choi, Y Togashi, M Soda, S Hatano, K Inamura, S Takada, ... Clinical cancer research 15 (9), 3143-3149, 2009	917	2009
Integrated molecular analysis of adult T cell leukemia/lymphoma K Kataoka, Y Nagata, A Kitanaka, Y Shiraishi, T Shimamura, J Yasunaga, ... Nature genetics 47 (11), 1304-1315, 2015	860	2015
Somatic RHOA mutation in angioimmunoblastic T cell lymphoma M Sakata-Yanagimoto, T Enami, K Yoshida, Y Shiraishi, R Ishii, Y Miyake, ... Nature genetics 46 (2), 171-175, 2014	743	2014
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers K Kataoka, Y Shiraishi, Y Takeda, S Sakata, M Matsumoto, S Nagano, ... Nature 534 (7607), 402-406, 2016	707	2016
A mouse model for EML4-ALK-positive lung cancer M Soda, S Takada, K Takeuchi, YL Choi, M Enomoto, T Ueno, H Haruta, ... Proceedings of the National Academy of Sciences 105 (50), 19893, 2008	705	2008
Frequent inactivation of A20 in B-cell lymphomas M Kato, M Sanada, I Kato, Y Sato, J Takita, K Takeuchi, A Niwa, Y Chen, ... Nature 459 (7247), 712-716, 2009	696	2009
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study T Seto, K Kiura, M Nishio, K Nakagawa, M Maemondo, A Inoue, T Hida, ... The lancet oncology 14 (7), 590-598, 2013	683	2013
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts K Takeuchi, YL Choi, M Soda, K Inamura, Y Togashi, S Hatano, ... Clinical cancer research 14 (20), 6618-6624, 2008	631	2008
EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers K Inamura, K Takeuchi, Y Togashi, K Nomura, H Ninomiya, M Okui, ... Journal of Thoracic Oncology 3 (1), 13, 2008	596	2008
Identification of novel isoforms of the EML4-ALK transforming gene in non–small cell lung cancer YL Choi, K Takeuchi, M Soda, K Inamura, Y Togashi, S Hatano, ... Cancer research 68 (13), 4971-4976, 2008	585	2008
Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients T Oyama, K Yamamoto, N Asano, A Oshiro, R Suzuki, Y Kagami, ... Clinical cancer research 13 (17), 5124-5132, 2007	566	2007
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset K Inamura, K Takeuchi, Y Togashi, S Hatano, H Ninomiya, N Motoi, ... Modern pathology 22 (4), 508-515, 2009	558	2009
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib R Katayama, L Friboulet, S Koike, EL Lockerman, TM Khan, JF Gainor, ... Clinical cancer research 20 (22), 5686-5696, 2014	336	2014
KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only Y Togashi, M Soda, S Sakata, E Sugawara, S Hatano, R Asaka, ... PloS one 7 (2), e31323, 2012	317	2012
Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations N Tomita, M Tokunaka, N Nakamura, K Takeuchi, J Koike, S Motomura, ... Haematologica 94 (7), 935-943, 2009	266	2009
Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype R Suzuki, Y Kagami, K Takeuchi, M Kami, M Okamoto, R Ichinohasama, ... Blood 96 (9), 2993-3000, 2000	259	2000
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer B Gong, K Kiyotani, S Sakata, S Nagano, S Kumehara, S Baba, B Besse, ... Journal of Experimental Medicine 216 (4), 982-1000, 2019	246	2019
TRANSPLANTATION-Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease Y Sakoda, D Hashimoto, S Asakura, K Takeuchi, M Harada, M Tanimoto, ... Blood 109 (4), 1756, 2010	211*	2010

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs